Asset
CONCIZUMAB
Revenue
No revenue reported in loaded filings.
Clinical trials (9)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT01631942 | phase1 | terminated | 2012-06-26 | 2012-09-04 | Novo Nordisk A/S | A Multi-centre, Open Labelled, Multiple Dosing Trial Investigating Safety, Pharmacokinetics and Pharmacodynamics of NNC 0172-2021 Administered Subcutaneously to Healthy Male Subjects and Haemophilia Subjects |
| NCT05135559 | phase3 | active_not_recruiting | 2022-03-24 | 2026-04-21 | Novo Nordisk A/S | A Research Study on How Well Concizumab Works for You if You Have Haemophilia A or B With or Without Inhibitors |
| NCT03196297 | phase2 | completed | 2017-08-16 | 2018-06-22 | Novo Nordisk A/S | A Trial Evaluating Efficacy and Safety of Prophylactic Administration of Concizumab in Patients With Severe Haemophilia A Without Inhibitors |
| NCT03196284 | phase2 | completed | 2017-08-10 | 2018-09-19 | Novo Nordisk A/S | A Trial Evaluating the Efficacy and Safety of Prophylactic Administration of Concizumab in Haemophilia A and B Patients With Inhibitors |
| NCT01555749 | phase1 | completed | 2012-03-12 | 2012-05-08 | Novo Nordisk A/S | Investigation of the Pharmacokinetics of NNC172-2021, at Two Different Dose Levels, in Healthy Japanese Subjects |
FDA applications (1)
| Application | Type | Applicant |
|---|---|---|
| BLA 761428 | BLA | NOVO NORDISK INC |
Marketed products (3)
- ALHEMO
- ALHEMO
- ALHEMO